Development of novel amisulpride-loaded solid self-nanoemulsifying tablets: preparation and pharmacokinetic evaluation in rabbits

References

• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58:173–182.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60:673–691.
   PubMed Web of Science ®Google Scholar
• Charman SA, Charman WN, Rogge MC, et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9:87–93.
   PubMed Web of Science ®Google Scholar
• Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv. 2011;8:1361–1378.
   PubMed Web of Science ®Google Scholar
• Dixit R, Nagarsenker M. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur J Pharm Sci. 2008;35:183–192.
   PubMed Web of Science ®Google Scholar
• Yi T, Wan J, Xu H, et al. A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs. Eur J Pharm Biopharm. 2008;70:439–444.
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180–190.
   PubMed Web of Science ®Google Scholar
• Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 2002;27:1071–1081.
   PubMed Web of Science ®Google Scholar
• Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2006;16:281–287.
   PubMed Web of Science ®Google Scholar
• Musenga A, Mandrioli R, Morganti E, et al. Enantioselective analysis of amisulpride in pharmaceutical formulations by means of capillary electrophoresis. J Pharm Biomedl Anal. 2008;46:966–970.
   PubMed Web of Science ®Google Scholar
• El Ela AA, Hartter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds – implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56:967–975.
   PubMed Web of Science ®Google Scholar
• Spireas S, Bolton SM. Liquisolid systems and methods of preparing same. U.S. Patent No. 6,096,337. Washington (DC): U.S. Patent and Trademark Office; 2000.
   Google Scholar
• Velasco M, Muñoz-Ruiz A, Monedero M, et al. Flow studies on maltodextrins as directly compressible vehicles. Drug Dev Ind Pharm. 1995;21:1235–1243.
   Web of Science ®Google Scholar
• Staniforth J, Aulton M. Powder flow. In: Hulton ME editor, Pharmaceutics: the science of dosage form design. Edinburgh: Churchill Livingstone; 2002. p. 197–210.
   Google Scholar
• Luner PE, Kirsch LE, Majuru S, et al. Preformulation studies on the s-isomer of oxybutynin hydrochloride, an improved chemical entity (ICE™). Drug Dev Ind Pharm. 2001;27:321–329.
   PubMed Web of Science ®Google Scholar
• Giunchedi P, Maggi L, Manna A, et al. Modification of the dissolution behaviour of a water‐insoluble drug, naftazone, for zero‐order release matrix preparation. J Pharm Pharmacol. 1994;46:476–480.
   PubMed Web of Science ®Google Scholar
• European Pharmacopoeia. Strasbourg: Council of Europe. 4th edition: 2002; p. 191–201, 984, 1169–1170, 1505–1507, 1828–1829, and 2435.
   Google Scholar
• British Pharmacopoeia. London: The Stationary Office. 2001; volumes I and II: p. 705–706, 1810–1813, Appendix XII, and A239–A324.
   Google Scholar
• Kudris IV, Skakun NN, Orlova IN, et al. Analysis of amisulpride in human plasma by SPE and LC with fluorescence detection. Chromatographia. 2011;73:67–74.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Bhyrapuneni G, Kandikere V, et al. Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg/mL using 100 µL of plasma. Biomed Chromatogr. 2008;22:1424–1433.
   PubMed Web of Science ®Google Scholar
• Mura P, Valleri M, Cirri M, et al. New solid self-microemulsifying systems to enhance dissolution rate of poorly water soluble drugs. Pharm Dev Technol. 2012;17:277–284.
   PubMed Web of Science ®Google Scholar
• Neusilin® – pharma excipients [Internet]. Toyama, Japan. Fuji Chemical Industry CO., LTD., 2010 [cited 2010 Sep 10]. Available from: http://www.fujichemical.co.jp/.
   Google Scholar
• Inugala S, Eedara BB, Sunkavalli S, et al. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: in vitro and in vivo evaluation. Eur J Pharm Sci. 2015;74:1–10.
   PubMed Web of Science ®Google Scholar
• Messa R, Ampati S. Formulation and development of modified released tablets containing antibiotic loaded microspheres. Int J Life Biosci. 2016; 2:90–97.
   Google Scholar
• Pandey P. Formulation and evaluation of herbal effervescent granules incorporated with Martynia Annua extract. J Drug Discov Ther. 2013;1:54–57.
   Google Scholar
• Takeuchi H, Nagira S, Yamamoto H, et al. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm. 2005;293:155–164.
   PubMed Web of Science ®Google Scholar
• Salama NN, Mohammad MA, Fattah TA. Thermal behavior study and decomposition kinetics of amisulpride under non-isothermal and isothermal conditions. J Therm Anal Calorim. 2015;120:953–958.
   Web of Science ®Google Scholar
• Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2008;69:993–1003.
   PubMed Web of Science ®Google Scholar
• Bioanalytical method validation. Guidance for industry. FDA, 2001. Available from: www.fda.gov/cder/guidance/index.htm.
   Google Scholar